Publications by authors named "S G Sallan"
Article Synopsis
- - Asparaginase-containing regimens for acute lymphoblastic leukemia (ALL) result in a significant prevalence of venous thromboembolism (VTE) among adolescents and young adults, with 1-year and 2-year cumulative incidences of 31.9% and 33.5%, respectively, particularly during the ASP-based consolidation phase.
- - The study revealed that overweight or obese patients had a higher risk of developing VTE (39.2%) compared to those with a normal BMI (29.0%), and overall survival rates were similar regardless of VTE occurrence, at around 91.5%.
- - Despite the frequent occurrence of VTE, especially types like pulmonary embolism and deep vein thrombosis,
Bone toxicities are common among paediatric patients treated for acute lymphoblastic leukaemia (ALL) with potentially major negative impact on patients' quality of life. To identify the underlying genetic contributors, we conducted a genome-wide association study (GWAS) and a transcriptome-wide association study (TWAS) in 260 patients of European-descent from the DFCI 05-001 ALL trial, with validation in 101 patients of European-descent from the DFCI 11-001 ALL trial. We identified a significant association between rs844882 on chromosome 20 and bone toxicities in the DFCI 05-001 trial (p = 1.
View Article and Find Full Text PDFPrinciples in the Development of Contemporary Treatment of Childhood Malignancies: The First 75 Years.
Cold Spring Harb Perspect Med
July 2024
Over the last 75 years, pediatric cancer has gone from nearly universally fatal, to having a >80% chance of long-term survival. Below we share highlights in this 75-year history, beginning with the "birth" of chemotherapy in treating childhood leukemia, through the development of multiagent chemotherapy, risk-stratified therapy, the use of molecular strategies in diagnosis and treatment, and adapting treatment to the needs of particularly vulnerable patient groups such as adolescents and young adults (AYAs). While pediatric leukemia treatment demonstrates the ever-improving cures achieved through iterative incorporation of novel discoveries, this experience is contrasted with that of osteosarcoma, where scientific advances made over recent decades have yet to be translated into meaningful improvements in long-term survival.
View Article and Find Full Text PDFArticle Synopsis
- - AYA patients with acute lymphoblastic leukemia (ALL) have poorer treatment completion rates compared to children, with only 60.8% of AYA patients completing their treatment versus 89.7% of children.
- - The main reason for this discrepancy is the higher incidence of early treatment failure among AYA patients (14.5% vs. 2.4%), while withdrawals due to toxicity or personal issues are less common but still higher in AYA patients (9.3% vs. 4.7%).
- - Staying on treatment for at least one year significantly improves survival rates, with AYA patients showing 5-year overall survival of 88.9%, but they completed critical asparaginase
Background: Children treated for acute lymphoblastic leukemia (ALL) receive prolonged treatment, resulting in toxicities that affect health-related quality of life (HR-QoL). Longitudinal assessment of HR-QoL allows improved understanding of experiences with ALL.
Procedure: Parent-proxy and child self-report HR-QoL over the first year of chemotherapy were evaluated in the context of DFCI Protocol 05-001, a phase 3 therapeutic trial for childhood ALL.